PL2768851T3 - Antygeny pochodzące z cytrulinowanego białka 14-3-3 oraz ich zastosowania w diagnozie reumatoidalnego zapalenia stawów - Google Patents

Antygeny pochodzące z cytrulinowanego białka 14-3-3 oraz ich zastosowania w diagnozie reumatoidalnego zapalenia stawów

Info

Publication number
PL2768851T3
PL2768851T3 PL12842377T PL12842377T PL2768851T3 PL 2768851 T3 PL2768851 T3 PL 2768851T3 PL 12842377 T PL12842377 T PL 12842377T PL 12842377 T PL12842377 T PL 12842377T PL 2768851 T3 PL2768851 T3 PL 2768851T3
Authority
PL
Poland
Prior art keywords
citrullinated
diagnosis
rheumatoid arthritis
antigens derived
antigens
Prior art date
Application number
PL12842377T
Other languages
English (en)
Inventor
Anthony Marotta
Original Assignee
Augurex Life Sciences Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Augurex Life Sciences Corp. filed Critical Augurex Life Sciences Corp.
Publication of PL2768851T3 publication Critical patent/PL2768851T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL12842377T 2011-10-21 2012-10-19 Antygeny pochodzące z cytrulinowanego białka 14-3-3 oraz ich zastosowania w diagnozie reumatoidalnego zapalenia stawów PL2768851T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550046P 2011-10-21 2011-10-21
PCT/CA2012/050748 WO2013056377A1 (en) 2011-10-21 2012-10-19 Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
EP12842377.9A EP2768851B1 (en) 2011-10-21 2012-10-19 Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
PL2768851T3 true PL2768851T3 (pl) 2018-05-30

Family

ID=48140274

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12842377T PL2768851T3 (pl) 2011-10-21 2012-10-19 Antygeny pochodzące z cytrulinowanego białka 14-3-3 oraz ich zastosowania w diagnozie reumatoidalnego zapalenia stawów

Country Status (17)

Country Link
US (2) US10132806B2 (pl)
EP (1) EP2768851B1 (pl)
JP (2) JP6844939B2 (pl)
KR (1) KR20140100939A (pl)
CN (1) CN104011068A (pl)
AU (1) AU2012325604B2 (pl)
BR (1) BR112014009536A2 (pl)
CA (1) CA2852758C (pl)
DK (1) DK2768851T3 (pl)
ES (1) ES2638331T3 (pl)
HK (1) HK1201538A1 (pl)
HU (1) HUE035999T2 (pl)
IL (1) IL232169B (pl)
IN (1) IN2014DN03200A (pl)
PL (1) PL2768851T3 (pl)
PT (1) PT2768851T (pl)
WO (1) WO2013056377A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140100939A (ko) * 2011-10-21 2014-08-18 오거렉스 라이프 사이언시스 코포레이션 시트룰린화된 14-3-3 유래 항원 및 류마티스 관절염 진단에서의 이의 용도
JP6543332B2 (ja) * 2014-05-05 2019-07-10 ノヴィオ テーハー ベー．フェー．Ｎｏｖｉｏ ＴＨ Ｂ．Ｖ． 関節リウマチの血清学的な診断方法
CN104262489B (zh) * 2014-09-30 2017-01-11 陈仁奋 一种环状瓜氨酸嵌合肽抗原及其应用
KR101758354B1 (ko) 2015-03-26 2017-07-17 한국과학기술연구원 신규한 시클릭 시트룰리네이티드 펩티드, 이를 포함하는 류마티스 관절염 진단용 조성물 및 이를 이용한 진단 방법, 및 류마티스 관절염 마커 스크리닝 방법
US20170038381A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
SG11201806696WA (en) * 2016-02-10 2018-09-27 Cayman Chemical Co Inc Anti-citrullinated hla polypeptide antibodies and uses thereof
CN106644985B (zh) * 2016-12-29 2021-02-05 广州市雷德生物科技有限公司 标志物及其应用、试剂盒、该标志物的检测方法
KR102529594B1 (ko) * 2021-06-23 2023-05-09 재단법인 아산사회복지재단 대동맥판막 협착증 진단 및 예후 예측을 위한 바이오마커로서 항-시트룰린화 펩티드 항체의 용도

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US6596476B1 (en) 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2239957A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5948765A (en) 1996-03-15 1999-09-07 Washington University Inhibition of intracellular signal transduction by 14-3-3-binding peptides
US5998149A (en) 1996-04-05 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Method of detecting transmissible spongiform encephalopathies
US5814507A (en) 1996-05-24 1998-09-29 Genentech, Inc. κ/μ-like protein tyrosine phosphatase, PTP λ
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
WO1998026293A1 (en) 1996-12-12 1998-06-18 Neuromark Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms
DE19810721A1 (de) 1998-03-12 1999-10-14 Werner Mueller Anwendung der 14-3-3 Proteine sowie Verfahren zur schnellen Bestimmung der 14-3-3 Proteine als sensitive Biomarker für Pollution u. a. mit polychlorierten Biphenylen (PCBs) und (Xeno)Östrogenen
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
WO2001070805A2 (en) 2000-03-17 2001-09-27 Gemini Science, Inc. Soluble mast cell function associated antigen (mafa) pharmaceutical compositions and methods of making and using them
KR100380147B1 (ko) 2001-01-18 2003-04-11 주식회사 엘지생명과학 류마티스성 자가면역 항체의 검출방법 및 검출키트
AU2002252011A1 (en) 2001-02-21 2002-09-12 Emory University 14-3-3 binding molecules as sensitizers for anticancer therapies
DE10131912A1 (de) 2001-06-06 2002-12-19 Werner E G Mueller Verwendung von 14-3-3 Proteinen und Verfahren zu deren Bestimmung
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
GB0208331D0 (en) 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
US7101962B2 (en) 2003-05-15 2006-09-05 Bristol-Myers Squibb Company Antibodies of the P2Y10 receptor useful in altering T lymphocyte function
EP1641935A2 (en) 2003-06-25 2006-04-05 Queen's University at Kingston Methods and formulations for diagnosing, monitoring, staging and treating heart failure
EP1701772A4 (en) 2003-11-21 2012-03-28 Univ Johns Hopkins BIOMOLECULAR SEPARATION PATTERNS AND USES
TWI281473B (en) 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
US7396654B2 (en) 2004-04-15 2008-07-08 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for traumatic brain injury
US20070253961A1 (en) 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007095250A2 (en) * 2006-02-13 2007-08-23 The Cleveland Clinic Foundation Compositions and methods for inhibiting optic nerve damage
AU2007247742B2 (en) 2006-05-09 2013-06-06 The University Of British Columbia Dissolved protein arthritis markers
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009046267A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
US7919262B2 (en) 2007-11-07 2011-04-05 The Uab Research Foundation 14-3-3 proteins for diagnosis of Parkinson's disease
JP5781764B2 (ja) 2007-11-27 2015-09-24 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア １４−３−３η抗体、並びに関節炎の診断及び治療のためのその使用
US20100016173A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
JP2012500964A (ja) 2008-05-09 2012-01-12 デューク ユニバーシティ 癌の検出と治療における自己抗体
BRPI1009573A2 (pt) * 2009-03-11 2017-07-18 Augurex Life Sciences Corp método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente.
CN102985819B (zh) 2010-07-09 2015-04-15 私募蛋白质体公司 肺癌生物标记及其用途
EP3029153B1 (en) 2010-09-27 2018-08-01 Somalogic, Inc. Mesothelioma biomarkers and uses thereof
KR20140100939A (ko) * 2011-10-21 2014-08-18 오거렉스 라이프 사이언시스 코포레이션 시트룰린화된 14-3-3 유래 항원 및 류마티스 관절염 진단에서의 이의 용도

Also Published As

Publication number Publication date
EP2768851A1 (en) 2014-08-27
IL232169B (en) 2018-12-31
WO2013056377A1 (en) 2013-04-25
EP2768851B1 (en) 2017-05-31
US20190310249A1 (en) 2019-10-10
ES2638331T3 (es) 2017-10-19
AU2012325604A1 (en) 2014-06-05
AU2012325604B2 (en) 2017-08-03
EP2768851A4 (en) 2015-03-11
JP2019081774A (ja) 2019-05-30
HK1201538A1 (en) 2015-09-04
BR112014009536A2 (pt) 2017-04-18
CN104011068A (zh) 2014-08-27
DK2768851T3 (en) 2017-09-18
HUE035999T2 (hu) 2018-06-28
IL232169A0 (en) 2014-06-30
US11913950B2 (en) 2024-02-27
US10132806B2 (en) 2018-11-20
US20140255957A1 (en) 2014-09-11
KR20140100939A (ko) 2014-08-18
IN2014DN03200A (pl) 2015-05-22
PT2768851T (pt) 2017-09-08
JP6844939B2 (ja) 2021-03-17
CA2852758A1 (en) 2013-04-25
JP2014530826A (ja) 2014-11-20
CA2852758C (en) 2020-12-29

Similar Documents

Publication Publication Date Title
HK1201538A1 (en) Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis 14-3-3
IL256728A (en) Systems for detecting drugs and autoantibodies against TNF
IL262559B (en) Use of the il-17 antibody to prepare a drug for the treatment of ankylosing spondylitis and rheumatoid arthritis
IL256716A (en) Antibodies against hla–b*27 and their uses
IL232001A0 (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
TWI560200B (en) Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
GB201014633D0 (en) Rheumatoid arthritis treatment
EP2542079A4 (en) TREATMENT OF RHEUMATOID ARTHRITIS BY MEANS OF A COMBINATION OF LAQUINIMOD AND METHOTREXATE
EP2611832A4 (en) ANTI-CXCL13 ANTIBODIES AND METHOD FOR THEIR USE
IL230529A0 (en) Antibodies against 2tie and their uses
EP2707013A4 (en) TESTS OF B-LYMPHOCYTES, T-CELLS AND ANTIBODIES SPECIFIC TO AN ANTIGEN OF THE CNS, AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF MULTIPLE SCLEROSIS
IL223290A (en) Anti-1α-il antibodies for the treatment of arthritis
EP2670731A4 (en) POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINE ACETYLCHOLIN RECEPTOR ALPHA 7 AND USES THEREOF
EP2613200A4 (en) TONER AND MANUFACTURING METHOD THEREFOR
ZA201309665B (en) Method for the diagnosis of rheumatoid arthritis
WO2012018776A9 (en) Treating rheumatoid arthritis with anti-il-19 antibody
HK1182440A1 (zh) 類風濕性關節炎的檢查方法及類風濕性關節炎檢查用試劑盒
GB201020085D0 (en) Methods and reagents for the treatment of arthritic disorders
IL286709A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
HK1249536A1 (zh) 用抗gm-csf抗體治療類風濕性關節炎
EP2669384A4 (en) METHOD FOR EVALUATING THE PRESENCE OF RHEUMATOID ARTHRITIS AND BIOMARK SUBSTITUTE USED IN THIS PROCESS
GB201311106D0 (en) Scribbing jig for the copying and transfer of data from iregular shapes tp regular shaped construction materials